Who are Pioglitazone and Glimepiride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amaryl, Glucotrol, Micronase, Aglicid, Diabinese, add-on sulphonylurea.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pioglitazone-and-glimepiride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pioglitazone and Glimepiride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pioglitazone and Glimepiride (Pioglitazone and Glimepiride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea [EPC].

marketed Sulfonylurea [EPC] PPARγ, ATP-sensitive potassium channel Small molecule Live · refreshed every 30 min

Target snapshot

Pioglitazone and Glimepiride (Pioglitazone and Glimepiride) — Takeda. Pioglitazone and glimepiride work together to improve glycemic control by reducing insulin resistance and stimulating insulin release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pioglitazone and Glimepiride TARGET	Pioglitazone and Glimepiride	Takeda	marketed	Sulfonylurea [EPC]	PPARγ, ATP-sensitive potassium channel
Amaryl	GLIMEPIRIDE	Sanofi	marketed	Sulfonylurea [EPC]	Sulfonylurea receptor 1, Kir6.2	1995-01-01
Glucotrol	GLIPIZIDE	Pfizer	marketed	Sulfonylurea [EPC]	Sulfonylurea receptor 1, Kir6.2	1984-01-01
Micronase	glibenclamide	Sanofi	marketed	Sulfonylurea	Sulfonylurea receptor 1, Kir6.2	1984-01-01
Aglicid	TOLBUTAMIDE		marketed	Sulfonylurea	Sulfonylurea receptor 1, Kir6.2	1961-01-01
Diabinese	CHLORPROPAMIDE	Pfizer	marketed	Sulfonylurea	Sulfonylurea receptor 1, Kir6.2	1958-01-01
add-on sulphonylurea	add-on sulphonylurea	Italian Society of Diabetology	marketed	Sulfonylurea	ATP-sensitive potassium channel (KATP channel)

Recent regulatory actions (last 90 days)

2026-03-04 — Glucotrol · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea [EPC] class)

Pfizer · 1 drug in this class
Sanofi · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pioglitazone and Glimepiride — Competitive Intelligence Brief. https://druglandscape.com/ci/pioglitazone-and-glimepiride. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab